The U.S. Food and Drug Administration (FDA) has formally agreed that the design and planned analysis of an upcoming Phase 3 trial testing privosegtor in people with optic neuritis could support a future application seeking the therapy’s approval if the trial succeeds. Optic neuritis, or inflammation of the optic nerve that carries information between the […]

The post Privosegtor optic neuritis clinical trial design gains FDA agreement appeared first on Multiple Sclerosis News Today.

Source: multiplesclerosisnewstoday.com